Advanced Sterilization Products receives FDA clearance for sterilization testing tool

Advanced Sterilization Products (ASP) have received clearance from the U.S. Food and Drug Administration for the STERRAD VELOCITY Biological Indicator (BI) System. This system, which tests tools for proper sterilization, is able to cut time when receiving test results from hours to 30 minutes.

"With a significantly shorter wait time, STERRAD VELOCITY reduces the risk of hospital sterilization departments releasing instruments prior to BI confirmation," said Amy Smith, Vice President, ASP Global Marketing. "Now they will finally be able to know with certainty that proper sterilization conditions have been achieved before the instruments are used in patients."

Sterilization in a hospital is key in ensuing patients are treated with clean instruments without the risk of acquiring an infection. With current methods, testing devices are slow in proving clear results as to whether a tool is properly sterilized, effecting patient outcomes. With the BI system, sterilization professionals are able to receive results faster and can push operating room workflow faster and with peace of mind the tool are cleaned.

"As the only company that offers an integrated, end-to-end sterilization solution, ASP is in a unique position to help customers elevate patient safety while also maximizing compliance and efficiency in their daily routine," said Smith. "Our complete ecosystem is designed to work together to provide the most accurate results. This ensures the lives of patients are better protected at a time when they are already vulnerable – when they are in hospitals and undergoing potentially life-changing procedures."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.